Biologics for Moderate to Severe Atopic Dermatitis

Describe your topic.: What is the place of systemic Biologics in treatment of moderate severe atopic dermatitis.

Describe why this topic is important.: Dupilumab -The First biologic agents, a selective IL-4-13 blocker Monoclonal antibody has been approved for moderate to severe atopic dermatitis patients. Where does it fit into the algorithm of treatment? No other systemic agent has been approved other than oral corticosteroids, which are ill advised according to standard guidelines.

Tell us why you are suggesting this topic.: The American Academy of Dermatology will soon be updating its guideline for the management of atopic dermatitis Further, the Food and Drug Administration (FDA) approved Dupilumab, an IL-4 and IL-13 inhibitor for the treatment of Atopic Dermatitis (AD). Dupilumab is the first systemic biologic approved for AD; therefore, its place in the treatment path of AD is unknown. The aim of this evidence review is to help determine an appropriate time during the treatment of AD to introduce the biologic dupilumab. The focus population should be adults with AD of any severity with or without concomitant diseases. The different types of treatment would include dupilumab monotherapy and combination therapy with other AD treatment. Such treatment may include phototherapy, topical corticosteroids, and systemic non-biologic therapies. The focus outcomes include improvement of disease signs and symptoms as well as quality of life (QoL) and financial burden.

Describe what you are doing currently and what you are hoping will change because of a new evidence report.: The evidence report would help the academy to decide if treatment recommendations should be developed on systemic agents as well as determine the strength of the recommendation.

How will you or your group use the information from a new evidence report?: The American Academy of Dermatology will soon be updating our guideline for the management of atopic dermatitis. We plan to use a new evidence report to draft evidence-based recommendations for the treatment of atopic dermatitis using systemic agents.

How would you or your group plan to disseminate information from the report? Who would you plan to disseminate it to?: The evidence report from EPC would be reviewed by nominated workgroup physicians in deciding treatment recommendations on biologic agents for atopic dermatitis guideline.

Do you know of organizations that could use an evidence report to change clinical practice? Are you a part of, or have you been in contact with, any organizations that might implement the research findings of an evidence report?

Information About You: (optional)

If you are you making a suggestion on behalf of an organization, please state the name of the organization.: American Academy of Dermatology

Effective Health Care Program